Gaining Stereoselectivity in Asymmetric Synthesis - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Gaining Stereoselectivity in Asymmetric Synthesis
Researchers use inorganic catalysts as an alternative to biocatalysts in the selective conversion of sugars to produce chiral building blocks.


Pharmaceutical Technology
Volume 37, Issue 2

References

1. Y. Román-Leshkov, "Sn-Beta Zeolites with Borate Salts Catalyze the Epimerization of Carbohydrates via an Intramolecular Carbon Shift," Nature Comnun., online, DOI:10.1038/ncomms2122, Oct. 9, 2012.

2. I. Shiina, J. Med Chem. 56 (1), 150–159 (2013).

3. J. Zhou, "Organocatalytic Asymmetric Synthesis of 3,3-Disubstituted Oxindoles Featuring Two Heteroatoms at C3 position," Chem. Commun., online, DOI: 10.1039/C3CC38819K, Jan. 23, 2013.

4. A.D. Lim, J.A. Codelli, and S.E. Reisman, "Catalytic Asymmetric Synthesis of Highly Substituted Pyrrolizidines," Chem. Sci., online, DOI: 10.1039/C2SC21617E, Nov. 13, 2012.

5. M.J. Abrahamson, Angew. Chem., Int. Ed. Engl., 51 (16), 3969–3972 (2012).

6. G. Sahoo, Angew. Chem., Int. Ed. Engl. 51 (52), 13144–13148 (2012).

7. W. Sommer and D. Weibel, Aldrich ChemFiles 8.2 (56) (2008).

8. D.H. Paull, J. Am. Chem. Soc., 134 (27), 11128–11131 (2012).

9. C. Drahl, Chem. & Eng. News 90 (28), 29 (2012).

Patricia Van Arnum is executive editor of Pharmaceutical Technology, 485 Route One South, Bldg F, First Floor, Iselin, NJ 08830 tel. 732.346.3072,
twitter@PharmTechVArnum


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here